Evommune, Inc. (EVMN)vsInsmed Inc (INSM)
EVMN
Evommune, Inc.
$23.16
+10.16%
HEALTHCARE · Cap: $735.46M
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 4565% more annual revenue ($606.42M vs $13.00M). EVMN leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
EVMN
Avoid25
out of 100
Grade: F
INSM
Hold39
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
No standout strengths identified
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : EVMN
EVMN has a balanced fundamental profile.
Bull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bear Case : EVMN
The primary concerns for EVMN are Revenue Growth, EPS Growth, Market Cap.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Key Dynamics to Monitor
EVMN profiles as a value stock while INSM is a turnaround play — different risk/reward profiles.
INSM is growing revenue faster at 1.5% — sustainability is the question.
EVMN generates stronger free cash flow (-17M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
INSM scores higher overall (39/100 vs 25/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Evommune, Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Evommune, Inc. is an innovative biotechnology company focused on developing cutting-edge therapeutics for the treatment of immunological disorders. With a robust pipeline designed to tackle significant unmet medical needs, Evommune leverages advanced research and technology to enhance immune response and patient outcomes. The company's dedication to scientific rigor and strategic partnerships supports its ambition to become a leader in the rapidly evolving field of immunotherapy. As Evommune progresses through clinical trials, it aims to deliver transformative solutions that could redefine care standards in immunology and provide renewed hope for patients.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?